# Provention Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/provention-bio

- Industry: Biotechnology
- Headquarters: Red Bank, US
- Website: www.proventionbio.com
- Total disclosed funding: $28M
- Latest round: Series A (Apr 25, 2017)
- Investors on record: 2

## About

Founded in 2016 and based in New Jersey, US, Provention Bio, Inc. operates as a biopharmaceutical company that develops therapeutics to prevent autoimmune and inflammatory diseases. In March 2023, Sanofi S.A., a portfolio company of Advanz Pharma Services (UK) Limited and Nordic Capital, agreed to acquire Provention Bio, Inc. for approximately USD 2.9 billion in equity, at USD 25 per share in cash. Ashleigh Palmer, co-founder and CEO of Provention Bio, is also the Founder and President of Creative BioVentures™ Corp. (CBV), and Heidy Abreu King-Jones, the chief legal officer, was the SVP and GC of Axcella Health.

The pipelines provided by the company include Intercepting Autoimmune Disease, Autoimmune Candidates, and Expanded Patient Access. The company has created a pipeline of investigational candidates that target upstream autoimmune pathways and even viral triggers with the goal of intercepting and preventing life-threatening and debilitating immune-mediated diseases, including type 1 diabetes (T1D), celiac disease, and lupus.

## Funding rounds

- Series A, Apr 25, 2017, $28M — Johnson & Johnson Innovation, JDRF T1D Fund

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series A